E.i. Dupont De Nemours and Company

Bristol-myers Squibb Compnay

Other

The Chemours Company Fc, LLC

Lg Chem, Ltd

University of North Carolina at Chapel Hill

E. I. Du Pont Nemours and Co.

E. I. Du Pont De Nemours + Company

Ying Wang

Norman Herron

Nora Sabina Radu

Viacheslav Alexandrovich Petrov

Daniel David Lecloux

Vladimir Grushin

Yan Shi

Steven Dale Ittel

Eric Maurice Smith

Peter Tai Wah Cheng

Alex Sergey Ionkin

Hao Zhang

Jun Li

Mark A Guidry

Lynda Kaye Johnson

Dean A Wacker

Lin Wang

Kerwin D Dobbs

Lawrence J Kennedy

Shiwei Tao

Jerald Feldman

James R Corte

Weiying Gao

Karen Anita Rossi

Jun Shi

Robert F Kaltenbach, Iii

Timothy Edward Hopkins

Sheng Peng

Wilson Tam

Vsevolod Rostovtsev

Weishi Wu

Peter T W Cheng

Stephen James Getty

Adam Fennimore

Elizabeth Forrester McCord

Michael Henry Howard, Jr

Steven Willis Shuey

Gang Wu

Charles D McLaren

Robert A Clement

Stephan James McLain

Shung C Wu

Jeffrey A Merlo

Alison Margaret Anne Bennett

David F Eaton

Stephen Y Chou

Jeffrey A Robl

Kiu-Seung Lee

Maurice S Brookhart

Peter Michael Murphy

Denis E Ryono

Albert Gordon Anderson

Robert Valentine Kasowski

Edward Bryan Coughlin

Rinaldo Soria Schiffino

Tianan Fang

Kristina Ann Kreutzer

Yanting Huang

Laurence Waino McKeen

Yulong Shen

Elisabeth Muriel Hauptman

Steven J Walker

Sutjano Jusuf

Jianxin Feng

Keith Joseph Kunitsky

Troy C Gehret

Xiaogan Liang

Giang Dong Vo

William R Ewing

Chunjian Liu

Annapurna Pendri

Ying Liu

Soong-Hoon Kim

Natesan Murugesan

Philip Michael Sher

Gerald Oronde Brown

Bruce A Ellsworth

Chongqing Sun

Guixue Yu

Gene M Rossi

Samuel Gerritz

Ji Jiang

Kyung-Ho Park

Kalindi Dogra

Doree F Sitkoff

Zhengxiang Gu

Frederick P Gentry

Xiang-Yang Ye

Wei Wang

Donald Keith Swanson

William J Marshall

John J Fitzgerald

William J Delaney

Amarendra B Mikkilineni

Ximao Wu

Justine Gabrielle Franchina

Matthias Broekema

Siddhartha Shenoy

Lucy M Clarkson

Karl Jeffery Sweetman

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

There is disclosed a compound having Formula I  In Formula, I: Aris selected from the group consisting of dibenzofuran, dibenzothiophene, or deuterated analogs thereof; Arand Arare the same or different and are hydrocarbon aryl, substituted derivatives thereof, or deuterated analogs thereof, with the proviso that Arand Arare not the same as Ar; a is 0; and Ar, Ar, and Arhave no additional amino substituents.

Electroactive materials

The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, X, X, and Xare each independently CRor N; provided that no more than two of X, X, X, or Xare N; Qis N or NR; one of Qand Qis CR, and the other is N or NR; and the dashed circle denotes optional bonds forming an aromatic ring; Yis O or NR; Yis &#x2014;CO&#x2014;, &#x2014;SO&#x2014;, or &#x2014;S(O(NH)&#x2014;; Yis O or NR; provided that (1) Yand Yare not both O, and (2) when Yis C(O), Yis not O; L is a covalent bond or Calkylene substituted with 0 to 4 R; Ris (&#x2014;CH)R; a is an integer of 0 or 1; Ris each independently halo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; Rand Rare independently hydrogen, Calkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Ris Calkyl, Chaloalkyi, Cdeuterated alkyl, Calkenyl, Ccycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, &#x2014;(Calkylene)&#x2014;(Ccycloalkyl), &#x2014;(Calkylene)&#x2014;(6 to 10-membered aryl), &#x2014;(Calkylene)&#x2014;(3 to 8-membered heterocyclyl), or &#x2014;(Calkylene)&#x2014;(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, Rand R, taken together with the N and 0 atoms which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R; or alternatively, (Rand R) or (Rand R), taken together with the atoms to which they are attached to, form a 5 to 8-membered heterocyclic ring moiety which is substituted with 0 to 3 R; Ris hydrogen, Calkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Rand Rare each independently hydrogen, halo, cyano, hydroxyl, amino, alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Ris halo, oxo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Rare each independently deuterium, halo, hydroxyl, amino, cyano, Calkyl, Cdeuterated alkyl, Calkenyl, Calkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R, taken together with the atom(s) to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R; Ris selected from &#x2014;CN, &#x2014;C(O)OR, &#x2014;C(O)NRR&#x2014;, &#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;SO&#x2014;OH, &#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;P(O)(OH), tetrazol-5-yl, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CH&#x2014;SO&#x2014;OH, &#x2014;CH&#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;P(O)(OH), tetrazol-5-ylmethylene; Ris Calkyl, Ccycloalkyl, haloalkyl, hydroxyalkyi, aminoalkyi, alkoxyalkyi, or haloalkoxyalkyi; Ris hydrogen or Calkyl; and Rand Rare each independently hydrogen, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, or haloalkoxy; and Ris halo, cyano, hydroxyl, amino, Calkyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors. 

Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Multicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid isoxazole azines as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid pyrazole azines as LPA antagonists

Cyclohexyl acid triazole azines as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Alkene compounds as farnesoid x receptor modulators

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Spirocyclic compounds as farnesoid X receptor modulators

The present invention relates to a method of detecting one or more metals in as liquid sample. The method includes the step of extracting the metal from the liquid sample and retaining the metal on a binding material. The detection of the extracted metal can be performed with the metal retained on the binding material or after the elution of the metal off the binding material.

Methods for analyzing ultra-trace amounts of metals in liquids

Growing community of inventors

Wilmington, DE, United States of America

Ying Wang